Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Stock Short Interest Report for September

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 164,782 shares, a growth of 95.6% from the September 15th total of 84,256 shares. Based on an average daily trading volume, of 2,143,151 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.5% of the shares of the stock are sold short.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ traded up $0.02 during midday trading on Thursday, hitting $0.80. The stock had a trading volume of 50,719 shares, compared to its average volume of 3,244,866. The company’s 50-day simple moving average is $1.04 and its 200 day simple moving average is $1.53. The firm has a market cap of $5.25 million, a P/E ratio of -0.39 and a beta of 2.06. Creative Medical Technology has a fifty-two week low of $0.62 and a fifty-two week high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Equities analysts expect that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

Analysts Set New Price Targets

CELZ has been the topic of a number of research analyst reports. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a report on Thursday, August 20th. Weiss Ratings lowered shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. Finally, Wall Street Zen upgraded shares of Creative Medical Technology from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc is a clinical-stage biotechnology company focused on developing regenerative medicine and cellular therapies. The company’s research uses adult stem cells and other cell-based approaches intended to address conditions with limited treatment options, including immune, neurological, metabolic and urological disorders.

Its development programs have included CaverStem, an autologous bone marrow-derived cell therapy platform being investigated for erectile dysfunction, as well as ImmCelz and NeuroCelz programs designed to explore cell-based treatments for immune-related and neurological conditions.